Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy
- Authors:
- Chiara Ghimenti
- Maurizia Mello-Grand
- Enrico Grosso
- Maria Scatolini
- Lea Regolo
- Alberto Zambelli
- Giovanna Chiorino
View Affiliations
Affiliations: Cancer Genomics Laboratory, Fondazione Edo ed Elvo Tempia Valenta, Biella, Italy, Unit of Senology, IRCCS Fondazione ‘Salvatore Maugeri’, Pavia, Italy, Unit of Medical Oncology, IRCCS Fondazione ‘Salvatore Maugeri’, Pavia, Italy
- Published online on: December 24, 2012 https://doi.org/10.3892/etm.2012.878
-
Pages:
902-906
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Aromatase inhibitors (AIs), such as anastrozole, are established in the treatment of hormone-dependent breast cancer. However, ~20% of patients with hormone receptor‑positive breast tumors treated with anastrozole do not respond and it remains impossible to accurately predict sensitivity. Since polymorphisms in the aromatase gene may influence the response to inhibitory drugs, we evaluated the presence of rs6493497 and rs7176005 polymorphisms (mapping in the 5'‑flanking region of the CYP19A1 gene coding for the aromatase protein) in a cohort of 37 patients with postmenopausal breast cancer who received three-month neoadjuvant treatment with anastrozole. We then investigated any association of the polymorphisms with changes in aromatase mRNA expression change and/or response to treatment. We also analyzed five miRNAs computationally predicted to target aromatase, to observe any association between their expression and sensitivity to anastrozole. Three samples carried the two polymorphisms and the remaining samples were wild-type for both, however, no association with response or with aromatase mRNA basal expression level or expression difference after therapy was observed. Polymorphic samples that were resistant to anastrozole showed no change or decrease in aromatase expression following AI treatment, whereas an increase in expression was observed for the polymorphic responsive samples. No statistically significant correlation was observed between miRNA and aromatase mRNA expression, or with response to anastrozole neoadjuvant treatment. These data indicate that the polymorphisms analyzed are not involved in aromatase activity and that other epigenetic mechanisms may regulate aromatase protein expression.
View References
|
1.
|
Yue W, Wang JP, Hamilton CJ, et al: In
situ aromatization enhances breast tumor estradiol levels and
cellular proliferation. Cancer Res. 58:927–932. 1998.PubMed/NCBI
|
|
2.
|
Brueggemeier RW, Hackett JC and Diaz-Cruz
ES: Aromatase inhibitors in the treatment of breast cancer. Endocr
Rev. 26:331–345. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Wang L, Ellsworth KA, Moon I, et al:
Functional genetic polymorphisms in the aromatase gene CYP19 vary
the response of breast cancer patients to neoadjiuvant therapy with
aromatase inhibitors. Cancer Res. 70:319–328. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Shibahara Y, Miki Y, Onodera Y, et al:
Aromatase inhibitor treatment of breast cancer cells increases the
expression of let-7f, a microRNA targeting CYP19A1. J Pathol.
227:357–366. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Ghimenti C, Mello Grand M, Regolo L,
Zambelli A and Chiorino G: Absence of K303R estrogen receptor-α
mutation in breast cancer patients with different response to
aromatase inhibitor anastrozole neoadjuvant treatment. Exp Ther
Med. 1:939–942. 2010.
|
|
6.
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
7.
|
Mello-Grand M, Singh V, Ghimenti C, et al:
Gene expression profiling and prediction of response to hormonal
neoadjuvant treatment with anastrozole in surgically resectable
breast cancer. Breast Cancer Res Treat. 121:399–411. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Xu S, Linher-Melville K, Yang BB, et al:
Micro-RNA378 (miR-378) regulates ovarian estradiol production by
targeting aromatase. Endocrinology. 152:3941–3951. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Colomer R, Monzo M, Tusquets I, et al: A
single-nucleotide polymorphism in the aromatase gene is associated
with the efficacy of the aromatase inhibitor letrozole in advanced
breast carcinoma. Clin Cancer Res. 14:811–816. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Garcia-Casado Z, Guerrero-Zotano A,
Llombart-Cussac A, et al: A polymorphism at the 3′-UTR region of
the aromatase gene defines a subgroup of postmenopusal breast
cancer patients with poor response to neoadjuvant letrozole. BMC
Cancer. 10:362010.
|
|
11.
|
Park IH, Lee YS and Lee KS: Single
nucleotide polymorphisms of CYP19A1 predict clinical outcomes and
adverse events associated with letrozole in patients with
metastatic breast cancer. Cancer Chemother Pharmacol. 68:1263–1271.
2011. View Article : Google Scholar : PubMed/NCBI
|
